Page last updated: 2024-12-06

soterenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

soterenol: adrenergic beta-2 agonist used as bronchodilator; it has a number of gastrointestinal side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search ETHANOLAMINES (75-86); RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID26162
CHEMBL ID30746
SCHEMBL ID119138
MeSH IDM0263184

Synonyms (24)

Synonym
soterenol
13642-52-9
CHEMBL30746 ,
bdbm50106804
n-[2-hydroxy-5-(1-hydroxy-2-isopropylamino-ethyl)-phenyl]-methanesulfonamide
n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide
2'-hydroxy-5'-(1-hydroxy-2-(isopropylamino)ethyl)methanesulfonailide
unii-9364w7589b
9364w7589b ,
soterenol [inn]
soterenolum [inn-latin]
2'-hydroxy-5'-(1-hydroxy-2-isopropylaminoethyl)methansulfonilid
soterenolum
methanesulfonamide, n-(2-hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-
(+/-)-2'-hydroxy-5'-(1-hydroxy-2-(isopropylamino)ethyl)methanesulfonamide
(+/-)-soterenol
soterenol [mi]
methanesulfonanilide, 2'-hydroxy-5'-(1-hydroxy-2-(isopropylamino)ethyl)-
2'-hydroxy-5'-(1-hydroxy-2-(isopropylamino)ethyl)methanesulfonamide
68939-21-9
SCHEMBL119138
Q27271566
DTXSID40864426
n-(2-hydroxy-5-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Cumulative dose-response curves to the beta agonists (-)-isoproterenol and (-)-soterenol were obtained after mixing each agonist with (+/-)-sotalol at fixed ratios (Q = [antagonist]/[agonist])."( On the use of a dynamic approach to the estimation of dissociation constants for reversible competitive antagonists.
Amidon, GL; Buckner, CK, 1981
)
0.49
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-3 adrenergic receptorHomo sapiens (human)Ki4.10000.00302.30986.0450AID41509
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1146184Selectivity ratio of ED25 for beta-1 adrenergic receptor in guinea pig right atria to ED50 for beta-2 adrenergic receptor in guinea pig tracheal chain1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID1147949Antagonism of morphine-induced analgesia in rat at 20 mg/kg, sc1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID1147932Analgesic activity in sc dosed rat by tail flick test1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID1147936Reversal of reserpine-induced ptosis in po dosed mouse1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID1147935Inhibition of reserpine-induced ptosis in po dosed mouse1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID215614Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly beta-adrenoceptors was determined.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Correlation between affinity toward adrenergic receptors and approximate electrostatic potentials of phenylethylamine derivatives. 1. Effects of the side chain.
AID1147939Partition coefficient, log P of the compound in CHCl3-H2O system at 4 ug/ml at pH 7.41976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID1146185Intrinsic activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle relative to papaverine1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID1146181Agonist activity at beta-1 adrenergic receptor in guinea pig right atria assessed as increase in contraction rate of spontaneously beating right atria1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID40683Selectivity as the ratio of Ki of beta-2 adrenergic receptor to the Ki of beta-3 adrenergic receptor.2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Beta 3 agonists. Part 1: evolution from inception to BMS-194449.
AID41510Human beta-3 adrenergic receptor agonist activity by measurement of cAMP accumulation levels in CHO membranes expressing human beta-3 receptor.2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Beta 3 agonists. Part 1: evolution from inception to BMS-194449.
AID1146183Intrinsic activity at beta-1 adrenergic receptor in guinea pig right atria assessed as increase in contraction rate of spontaneously beating right atria relative to isoproterenol1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
AID41509Binding affinity against CHO cells transfected with human beta-3 adrenergic receptor in the presence of [125I]iodocyanopindolol2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Beta 3 agonists. Part 1: evolution from inception to BMS-194449.
AID1147931Analgesic activity in sc dosed mouse assessed as reduction in phenylalanine-induced writhing1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID42021Selectivity measured as the ratio of Ki of Beta-1 Adrenergic receptor to the Ki of Beta-3 Adrenergic receptor2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Beta 3 agonists. Part 1: evolution from inception to BMS-194449.
AID1146180Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Adrenergic agents. 8.1 Synthesis and beta-adrenergic agonist activity of some 3-tert-butylamino-2-(substituted phenyl)-1-propanols.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (68.75)18.7374
1990's3 (18.75)18.2507
2000's2 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.08 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]